Suven Life Sciences Limited - Due diligence report
A 360° intelligence report on Suven Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress si…
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Suven Life Sciences — 360° Intelligence Report
Generated from MCA filings & public recordsSuven Life Sciences is assessed as Moderate with a Trust Score of 56/100. Suven Life Sciences is an active public limited indian non-government company incorporated in 1989, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.
Report generated on 21 Nov 2026 from the latest processed filings. Suven Life Sciences Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
Score Card
Higher is safer · rule-based & explainableFinancial Intelligence Dashboard
Consolidated · 0 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
Credit & Compliance Intelligence
Why the scores are what they are- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
Charges position: 0 open ( 48.0 cr ) · 14 satisfied ( 12.5 cr ).
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 5 | 48.0 cr |
| Bank Of Bahrain And Kuwait Bsc | 2 | 48.0 cr |
| Bank Of India | 1 | 48.0 cr |
| State Of Bank Patiala | 1 | 48.0 cr |
| Industrial Development Bank Of India | 1 | 48.0 cr |
| Export -- Import Bank Of India | 1 | 48.0 cr |
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2025).
- Flagged by authority: BSE.
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (1 disclosure(s)).
- 2 active GST registration(s).
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SANTANU MUKHERJEE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MOHAN KUMAR MALLARAPU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUDHARANI JASTI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATESWARLU JASTI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VAJJA SAMBASIVA RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SEYED EHTESHAM HASNAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Shrenik Soni | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANANTHASAI PADMAJA JASTHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
Ownership & Group Intelligence
As per FY 2025 annual returnPromoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED | Holding Company | 74.00% |
Key managerial personnel: MOHAN KUMAR MALLARAPU (CFO) · SUDHARANI JASTI (Whole-time director) · VENKATESWARLU JASTI (Managing Director)
Full shareholding pattern, group structure & capital events →
Risk Intelligence Center
Growth 45 · Distress 50Stakeholder Verdicts
Vendor · Banker · Investor- Check the compliance flags before onboarding.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
MCA Filings & Events Timeline
Latest 15 eventsKey Observations
Auto-generated from the data above| Company | CIN | Location |
|---|---|---|
| Ssr Green Tech Energy Private Limited | U31900OR2018PTC029482 | Nuapada, Orissa, India |
| Aring Prodev Private Limited | U73200KA2017PTC102876 | Bangalore, Karnataka, India |
| Jubilant Therapeutics India Limited | U74994UP2019PLC114901 | Noida, Uttar Pradesh, India |
| Batavia Pharma Private Limited | U24304PN2016PTC166674 | Pune, Maharashtra, India |
| Evoq Remedies | L46209GJ2010PLC059692 | Ahmedabad, Gujarat, India |
| Anek Prayog Private Limited | U73100MH1979PTC021320 | Mumbai, Maharashtra, India |
| Vivo Bio Tech | L65993TG1987PLC007163 | Hyderabad, Telangana, India |
| George Institute For Global Health | U74900TG2007NPL055085 | Khairatabad, Telangana, India |
Who Uses This Report
CA · CS · Banker · Investor · VendorVerify Suven Life Sciences before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Track statutory health of Suven Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Current banker verdict: Enhanced diligence advised. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Suven Life Sciences - screening before a deeper diligence.
Vendor verdict: Caution indicated. Trust score 56/100, distress signals and MSME payment-delay disclosures - know whether Suven Life Sciences pays its suppliers before you extend credit terms.
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Suven Life Sciences - groundwork for KYC, onboarding and disputes.
Frequently Asked Questions
Is Suven Life Sciences an active company?
Suven Life Sciences has MCA status “Active” with a compliance score of 30/100 (Caution Indicated).
Is Suven Life Sciences financially healthy?
Suven Life Sciences has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Suven Life Sciences?
Its overall Trust Score is 56/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Suven Life Sciences?
The ultimate holding entity is JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED. 8 active director(s) are on record.
Does Suven Life Sciences have loans or charges against its assets?
No open charges - all 14 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Suven Life Sciences up to date with its ROC filings?
Balance sheet slightly behind (Mar 2025). Overall compliance score: 30/100 (Caution Indicated).
Is it risky to lend to Suven Life Sciences?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Enhanced diligence advised.